Buy ATTRUBY (acoramidis) acoramidis

ATTRUBY (acoramidis) is an FDA-approved oral medication developed by BridgeBio Pharma, Inc. for treating cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM). Designated as an orphan drug, ATTRUBY represents a significant therapeutic advance in cardiology for this rare and progressive cardiac condition.

Strength

356 mg/1

Pack Size

4 DOSE PACK in 1 CARTON (82228-712-28) / 1 BLISTER PACK in 1 DOSE PACK / 28 TABLET, FILM COATED in

Manufacturer / TM Owner

BridgeBio Pharma, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

ATTRUBY is indicated for patients with cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM), a rare progressive disease characterized by abnormal amyloid protein deposits in the heart. The drug targets wild-type ATTR-CM and hereditary ATTR-CM (hATTR-CM) patients experiencing cardiac dysfunction. Acoramidis works by stabilizing transthyretin (TTR) tetramers, preventing their dissociation into monomers that misfold and aggregate into amyloid fibrils. This mechanism halts disease progression and preserves cardiac function. ATTRUBY is administered orally, offering a convenient treatment option for patients with symptomatic ATTR-CM who face significant morbidity and mortality risks. The drug addresses an unmet medical need in this patient population, where limited therapeutic options previously existed for slowing cardiac deterioration and improving quality of life.

Side Effects

Common adverse events associated with ATTRUBY include gastrointestinal disturbances, peripheral edema, and fatigue. Serious adverse events may include cardiac arrhythmias, worsening heart failure, and hepatotoxicity. Patients require regular cardiac monitoring including echocardiography and biomarker assessment (NT-proBNP, troponin). Liver function tests should be monitored periodically due to potential hepatic effects. Blood pressure monitoring is recommended as hypertension may occur. Renal function should be assessed regularly, particularly in patients with baseline renal impairment. Any signs of cardiac decompensation, syncope, or severe edema warrant immediate medical evaluation.

Precautions & Warnings

ATTRUBY is contraindicated in patients with severe hepatic impairment. Caution is advised in patients with moderate renal or hepatic dysfunction, requiring dose adjustments or careful monitoring. Pregnancy category data should be reviewed with healthcare providers, as animal studies may indicate fetal risk. Pediatric use has not been established; safety and efficacy in children remain unknown. Elderly patients may require careful dose titration and enhanced monitoring. Patients with baseline cardiac conduction abnormalities or on concurrent cardiac medications need close supervision. ATTRUBY should not be used in patients with hypersensitivity to acoramidis or any formulation components.

Avoid Interactions

ATTRUBY may interact with strong CYP3A4 inhibitors and inducers, potentially altering drug concentrations. Concurrent use with other cardiac medications, particularly those affecting heart rate or contractility, requires monitoring. NSAIDs and other nephrotoxic agents may increase renal impairment risk in susceptible patients. Grapefruit juice should be avoided as it may inhibit CYP3A4 metabolism. Patients on anticoagulants or antiplatelet agents require standard monitoring protocols. Consultation with pharmacists is recommended when initiating concurrent medications to assess interaction potential.

Frequently Asked Questions

ATTRUBY (acoramidis) is used to treat cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM), a rare progressive heart disease. It works by stabilizing transthyretin protein to prevent amyloid formation and cardiac deterioration. ATTRUBY is indicated for both wild-type and hereditary forms of ATTR-CM.

ATTRUBY is administered orally as a tablet, typically taken once or twice daily as directed by a healthcare provider. The exact dosing regimen should be determined by a cardiologist or specialist experienced in ATTR-CM management. Patients should take ATTRUBY consistently and follow their prescribed schedule.

Common side effects include gastrointestinal symptoms, peripheral edema, and fatigue. Most adverse events are mild to moderate in severity. Patients should report any persistent or concerning symptoms to their healthcare provider immediately.

ATTRUBY is manufactured by BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for rare genetic diseases.

Yes, ATTRUBY has been designated as an orphan drug by the FDA due to its indication for ATTR-CM, a rare disease affecting fewer than 200,000 people in the United States. This designation provides regulatory incentives and support for development and commercialization of this important therapeutic.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.